Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on February 26, 2008
JNCI Journal of the National Cancer Institute 2008 100(5):290-291; doi:10.1093/jnci/djn038
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/5/290    most recent
djn038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kiviat, N. B.
Right arrow Articles by Feng, Q.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiviat, N. B.
Right arrow Articles by Feng, Q.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Screening for Cervical Cancer in the Era of the HPV Vaccine—The Urgent Need for Both New Screening Guidelines and New Biomarkers

Nancy B. Kiviat, Stephen E. Hawes, Qinghua Feng

Affiliation of authors: Departments of Pathology (NBK, QF) and Epidemiology (SEH), University of Washington, Seattle, WA

Correspondence to: Nancy B. Kiviat, MD, Harborview Medical Center, 325 9th Ave, Rm 2E-H87, Seattle, WA 98104 (e-mail: nbk@u.washington.edu).

The first 10% of the full text of this article appears below.

Over the past 25 years, not only have "high-risk" human papillomaviruses (HPVs) been identified as the causal agents of cervical cancer, but also accurate clinical assays have been developed for their detection. Most important, prophylactic vaccines to prevent infection with those high-risk HPVs most commonly found in cervical cancers have recently become available. Unfortunately, however, cervical cancer screening will need to continue for the foreseeable future because prophylactic vaccines cover only a subset of those HPV types that cause . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 287. [Extract] [Full Text] [PDF]